Invenra
505 South Rosa Road
Suite 235
Madison
Wisconsin
53719
United States
Tel: 608-441-8319
Website: http://www.invenra.com
Email: info@invenra.com
About Invenra
Invenra is a pre-clinical stage bio-pharmaceutical company focused on discovering the next generation of best-in-class biologics, with an emphasis on monoclonal antibodies (mAbs), bispecific antibodies using their proprietary B-Body™ and TAIL™ platforms, empowered mAbs and their derivatives. Invenra’s proprietary technology combines state-of-the-art libraries and in vitro display methodologies, cell-free expression of full-length antibodies and extreme miniaturization enabling the screening of unprecedented numbers of full-length antibodies in direct phenotypic assays. For the first time, all potential antibodies of interest in a library can be screened for biological activity and other desirable traits. Invenra’s platform technology will produce the broadest epitope coverage possible and co-optimization of antibody design goals with biological activity will result in the highest caliber lead therapeutics.YEAR FOUNDED:
2011
LEADERSHIP:
Founder and CEO: Roland Green
JOBS:
Please click here for Invenra job opportunities.
10 articles about Invenra
-
Invenra to Present Preclinical Data on INV322, A Next Generation Tumor Treg Depleter
9/20/2022
Invenra announced that Chief Scientific Officer Daniel Pereira, Ph.D., will present preclinical data supporting the ongoing development of INV322, an antibody-based cancer therapeutic.
-
Invenra, Inc. Appoints Daniel S. Pereira, Ph.D., as Chief Scientific Officer
1/5/2022
Invenra, Inc., a biotechnology company focused on the discovery and development of multispecific antibodies for immuno-oncology, today announced the appointment of Daniel S. Pereira, Ph.D., as Chief Scientific Officer.
-
Invenra Announces Expansion of Collaboration with Exelixis
10/31/2019
Invenra Inc. announced that it has expanded its collaboration with Exelixis, Inc.
-
Invenra and WARF Initiate a Collaboration to Discover and Develop Novel Therapeutics to Fight Neuroblastoma in Children
1/31/2019
Invenra and WARF (Wisconsin Alumni Research Foundation) today announced they have entered into a collaboration to discover and develop a bispecific antibody therapeutic for the treatment of neuroblastoma, a cancer that is the third most common
-
Exelixis and Invenra Enter Into Collaboration to Discover and Develop Novel Biologics to Treat Cancer
5/2/2018
Exelixis, Inc. announced that it has entered into a collaboration with Invenra, Inc.
-
Invenra Adds Experienced Clinical Immuno-Oncologist, Dr. Paul Sondel To The Advisory Team
9/26/2017
-
Invenra Enters Collaboration Agreement With Merck & Co. To Identify Therapeutic Antibodies Against Challenging Target
7/18/2017
-
Invenra Appoints Anu Hoey Vice President, Corporate Development
5/16/2017
-
Invenra Appoints Anu Hoey Vice President, Corporate Development
5/16/2017
-
Invenra And QIMR Berghofer Medical Research Institute Enter Collaboration To Discover Therapeutic Antibodies Against Novel Target
3/1/2017